[Maxaquin and ciprofloxacin in the treatment of complicated and recurrent urinary infections in adults]
- PMID: 8015241
[Maxaquin and ciprofloxacin in the treatment of complicated and recurrent urinary infections in adults]
Abstract
Clinical efficacy of maxaquin versus ciprofloxacin against complicated or/and recurrent urinary infections (62 patients primarily with chronic pyelonephritis with nephrolithiasis) proved higher (92.3% vs 80.0%) in equal microbiological activity (73.2% vs. 73.4%) of the drugs. Maxaquin was less active in enhancing the culture resistance. Both quinolones had no negative effects on the studied systems of the body's antiinfectious resistance and promoted partial correction of dysbiotic manifestations on the colon mucosa. Side effects of both drugs occurred with similar frequency and severity, starting earlier in administration of maxaquin. The authors offer to manage urinary infections in adults effectively with maxaquin in a dose 400 mg once a day and ciprofloxacin in a dose 500 mg twice a day by 7-14-day courses.
Similar articles
-
Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis.J Urol. 1995 Jul;154(1):19-24. J Urol. 1995. PMID: 7776420 Clinical Trial.
-
Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women.J Fam Pract. 1992 Feb;34(2):180-4. J Fam Pract. 1992. PMID: 1310715 Clinical Trial.
-
Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study.J Chemother. 1996 Jun;8(3):210-3. doi: 10.1179/joc.1996.8.3.210. J Chemother. 1996. PMID: 8808718 Clinical Trial.
-
[Urinary tract infections: risk factors and therapeutic trends].Recenti Prog Med. 1997 Feb;88(2):65-8. Recenti Prog Med. 1997. PMID: 9148368 Review. Italian.
-
Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections.Int J Antimicrob Agents. 2004 Mar;23 Suppl 1:S54-66. doi: 10.1016/j.ijantimicag.2003.12.005. Int J Antimicrob Agents. 2004. PMID: 15037329 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical